Alternative metrics for assessing clinical benefit with immunotherapy in oncology

Eitemau Tebyg

• Assessment of Whether the American Society of Clinical Oncology’s Value Framework and the European Society for Medical Oncology’s Magnitude of Clinical Benefit Scale Measure Absolute or Relative Clinical Survival Benefit: An Analysis of Randomized Clinical Trials
  gan: Saluja, Ronak, et al.
  Cyhoeddwyd: (2019)
• Current challenges for assessing the long-term clinical benefit of cancer immunotherapy: a multi-stakeholder perspective
  gan: Quinn, Casey, et al.
  Cyhoeddwyd: (2020)
• Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic
  gan: Chan, T A, et al.
  Cyhoeddwyd: (2019)
• The impact of additive or substitutive clinical study design on the negotiated reimbursement for oncology pharmaceuticals after early benefit assessment in Germany
  gan: C. M. Dintsios, et al.
  Cyhoeddwyd: (2020-03-01)
• The impact of additive or substitutive clinical study design on the negotiated reimbursement for oncology pharmaceuticals after early benefit assessment in Germany
  gan: Dintsios, C. M., et al.
  Cyhoeddwyd: (2020)